Australia: Australia has become the first country to officially classify psychedelics as medicines at a national level. In a groundbreaking decision earlier this year, the country’s conservative medicine regulator granted approval for the use of psychedelics in therapy sessions. The move allows the use of psilocybin, the active compound in magic mushrooms, for treating treatment-resistant depression and MDMA, commonly known as ecstasy, for post-traumatic stress disorder (PTSD).

The new regulations will be a significant milestone in the field of psychedelic medicine. While access to these drugs will initially be limited and expensive, experts and patients alike are celebrating the development as a landmark moment.

However, major health organisations have issued warnings and emphasised the need for caution. While other countries, including Switzerland, Canada, and Israel, have explored the use of psychedelics for compassionate purposes, Australia is the first to officially classify them as medicines at a national level. Psychedelic clinics are already operating legally in countries such as Jamaica and Costa Rica.

The implementation of clinical prescriptions for these drugs in Australia, as well as the associated pricing, will be closely monitored. The history of MDMA, which was initially developed as an appetite suppressant in 1912 and later used in therapy sessions until its outlawing in the mid-1970s, adds complexity to the discussion. In Australia, it gained popularity in the 1980s as a party drug before being criminalised in 1987.

Recent research has rekindled interest in the therapeutic potential of MDMA and psilocybin. Trials have shown that these substances can rapidly improve symptoms of severe depression, although the specific mechanisms are not yet fully understood.

Mind Medicine Australia (MMA), a charity organisation that has actively campaigned for psychedelic treatments, is involved in training health professionals responsible for procuring and prescribing these drugs. Psychiatrists seeking authorization as prescribers must undergo an ethics committee review and gain approval from Australia’s drug regulator, the Therapeutic Goods Administration (TGA). They will also need to source and supply both MDMA and psilocybin.

Despite the TGA’s approval, major medical and mental health bodies in Australia remain cautious about embracing psychedelic treatments. Mr. Kristen Morely, a professor of addiction medicine at the University of Sydney, noted the considerable caution expressed by the scientific and medical communities.

WORLD ROUNDUP: Scientists detect cosmic hum from gravitational waves